AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally.
The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement.
The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function.
It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting.
The company was founded in 2011 and is headquartered in Durham, North Carolina.
Country | United States |
IPO Date | Feb 11, 2021 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 1,030 |
CEO | Robert E. Claypoole |
Contact Details
Address: 4721 Emperor Boulevard Durham, North Carolina United States | |
Website | https://www.bioventus.com |
Stock Details
Ticker Symbol | BVS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001665988 |
CUSIP Number | 09075A108 |
ISIN Number | US09075A1088 |
Employer ID | 81-0980861 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Robert E. Claypoole | President, Chief Executive Officer & Director |
Mark L. Singleton | Senior Vice President & Chief Financial Officer |
Anthony D'Adamio J.D. | Senior Vice President, General Counsel & Corporate Secretary |
Dave Venner | Senior Vice President & GM of Surgical |
David Crawford | Vice President of Investor Relations & Treasurer |
Helen Leupold | Senior Vice President & Chief Human Resources Officer |
Katrina J. Church J.D. | Senior Vice President & Chief Compliance Officer |
Larry Chen | Managing Director of China & Asia Pacific |
Mike Crowe B.S., M.B.A. | Senior Vice President of Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 26, 2024 | 4 | Filing |
Dec 26, 2024 | 4 | Filing |
Dec 26, 2024 | 4 | Filing |
Dec 23, 2024 | 4 | Filing |
Dec 23, 2024 | 4 | Filing |
Dec 23, 2024 | 4 | Filing |
Nov 14, 2024 | SCHEDULE 13G/A | [Amend] Filing |
Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 05, 2024 | 10-Q | Quarterly Report |
Nov 05, 2024 | 8-K | Current Report |